Impact of a risk-sharing agreement in rheumatoid arthritis in Spain

Carlos Gustavo García-Collado, Juan Enrique Martínez-de-la-Plata, María del Mar Maldonado Montoro, Alberto Jiménez Morales, Miguel Ángel Calleja Hernández and Fernando Martínez Martínez

Health Policy, 2021, vol. 125, issue 3, 335-340

Abstract: Risk-sharing agreements(RSA) allow decision-makers to manage the uncertainty associated with effectiveness and costs of treatments. Our objective was to estimate the economic impact of RSA implementation on treatment of patients diagnosed with rheumatoid arthritis(RA) with certolizumab pegol(CZP) and assess the potential impact of alternative RSA.

Keywords: Risk-sharing agreement; Pay for performance; Certolizumab; Spain; Rheumatoid arthritis (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851020302815
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:125:y:2021:i:3:p:335-340

DOI: 10.1016/j.healthpol.2020.11.009

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().